StockGuru Welcomes First China Pharmaceutical Group, Inc. (OTCBB- FCPG) – China is arguably the most attractive emerging pharmaceutical market. Read Why!

by ·



StockGuru Newsletter

You are subscribed as

StockGuru Welcomes First China Pharmaceutical Group, Inc. (OTCBB: FCPG)

First China Pharmaceutical Group, Inc. (OTCBB: FCPG) StockGuru Profile – Company Website

Dear Members, China is arguably the most attractive emerging pharmaceutical market. Read Why! StockGuru brings this Company to you very close to its United States public inception! This represents and amazing opportunity.

***FULL PROFILE FOLLOWS BELOW***

Thank You, John Pentony Publisher, StockGuru.com

First China Pharmaceutical Group, Inc. (OTCBB: FCPG) StockGuru Profile – Company Website

 

First China Pharmaceutical Group, Inc. (OTCBB: FCPG) This profitable drug logistics and distribution pharmaceutical Company in China operates through drug stores, clinics and hospitals in China has a market cap in the $40M range, currently. Additionally, it operates the wholesale distribution of medicine products, chemical agents, antibiotics, biochemistry drugs and biological preparations to hospitals and Company stores. Currently the Company has over 4,700 customers and supplies approximately 10% of their inventories. The company was founded in 2002 with offices and warehouse space in Kunming City, Yunnan Province and originally achieved profitability in 2003. Extensive plans for growth are planned.

Profitable Established Pharma in Yunnan Province First China Pharmaceutical Group is a profitable provincial pharmaceutical distributor providing drug logistics and distribution in Yunnan Province, China (pop. 45,710,000). First China Pharmaceutical plans to rapidly expand from a provincial pharmaceutical distributor in Yunnan Province to a national distributor servicing many provinces. The ordering, fulfillment and logistics network will enhance the ability to attract and acquire other provincial, county and municipal pharmaceutical distributors over the next 24 to 48 months. First China Pharmaceutical Group is the only pharmaceutical distribution company in Yunnan Province licensed to fill orders over the internet. Provincial and National governing bodies have placed an indefinite moratorium on granting new internet distribution licenses. China’s pharmaceutical industry will grow at an average annual rate of 22% from 2010 to 2019, according to a June 23, 2009, report issued by China’s Southern Medicine Economic Research Agency.

China’s Pharma Market Growth Universal, safe, affordable and effective basic healthcare was set as a goal for the nation’s 1.3 billion population by 2020 in April of 2009. (OECD, “Economic Survey of China”, February 2010) China’s pharmaceuticals market, including nutritional products and consumer drugs, is anticipated to:

2015: more than double to $110 billion from $44 billion in 2008, Credit Suisse AG estimated in a November 2009 report

2018: expand to a market of $132.7 billion. (BMI, “China Pharmaceuticals and Healthcare Report Q4”, October 2009)

Annual Growth of China’s pharmaceutical market is expected to continue to grow at a 20% plus annual pace. (IMS Health, “IMS Market Prognosis”, April 10, 2010).

An additional $124 billion is anticipated to be spent on healthcare between 2009 and 2011. Key Pharma drivers of market expansion are China’s introduction of:

Universal health insurance Booming economy More chronic diseases Aging population

Advantages of FCPG:

Exclusive Internet Distribution License in Yunnan Province $25.3 Million in Revenue for 2009 and Six Month 2010 Revenue Looking Good Thriving Chinese Pharmaceutical Market with Boomers and National Healthcare Coverage

FCPG has a sales network that covers the entire Yunnan Province of China. The Company’s strategy is to build a nationwide pharmaceutical distribution network throughout China.

How They were there first and now huge barriers to entry exist in terms of licensing and internet sales.

Why You have an established Company with an Internet Distribution License – virtually impossible to obtain currently.

Who To the expanding boomer class and the strongly underwritten medical program the PRC has initiated.

First China Pharmaceutical ‘s Sales for the Six Months Ended June 30, 2010 Totaled $13.9M USD This first six month 2010 result represents an increase of 15.8% from $12M USD year over year. The key reason for the 2010 improvement was First China Pharmaceutical’s ability to fulfill orders over the internet in 2010.

Six Months 6/3/2010

Gross Revenue $ 13,878,888

Net Revenue $ 1,678,000

Net Sales as Percentage of Gross 12%

Only License of Internet Pharmacy Information Service in Yunnan Province First China Pharmaceutical Group (OTCBB: FCPG) is the only pharmaceutical distribution company in Yunnan Province that has obtained government approval to fill orders over the internet. The Company possesses the only “License of Internet Pharmacy Information Service” in Yunnan Province issued by the Yunnan Food and Drug Administration in November 2009, allowing the Company to bypass municipal and county pharmaceutical distributors and provide products directly to customers. Products are offered to customers at a significantly lower price than its major competitors while maintaining its margins. This also creates a barrier to entry because reviewing applications for the ordering of drugs over the internet has been suspended by the Chinese government due to several cases of fraud, where prescription drugs have fallen into the hands of unlicensed practitioners providing strategic advantage to FCPG in the short term. This increase in sales was primarily due to the growth of business resulting from internet sales beginning in November of 2009 and the sales of higher priced products supported by increased selling efforts. Net income has shown a steady increase from 2007 to 2009. During 2010 progress has continued while FCPG has instituted a more efficient order processing and fulfillment using the internet has increased productivity and enabled First China Pharmaceutical to order larger inventories and realize volume discounts. The Q3 10Q should represent a crucial evaluation of ongoing increases in efficiencies as interpreted in net sales. In November 2009, First China Pharmaceutical received government approval to accept and fulfill orders over the internet and began to realize the benefits of internet orders in the first quarter of 2010.

The Business Plan First China Pharmaceutical anticipates its business model will change to leverage the efficiencies of internet ordering and fulfillment. The product line is anticipated to be expanded from approximately 5,000 products to approximately 30,000 products by the end of 2010. The broader product line will include significantly more Western drugs as well as additional traditional Chinese drugs and herbs. It is estimated that the broader product line will ensure that customers will be able to order 80% to 90% of the products they carry directly from First China Pharmaceutical. First China Pharmaceutical will leverage its ability to fulfill orders over the internet by bypassing two levels of distributors and approximately 40% in total pricing mark-up. By bypassing city and county distributors, First China Pharmaceutical will be able to achieve higher margins while providing pharmaceuticals to pharmacies, hospitals and clinics at costs below the traditional distribution model. This competitive pricing advantage is anticipated to expand profit margins. The potential exists that numerous provincial, county and municipal pharmaceutical distributors will be displaced utilizing the FCPG sales network in over 15 regions in Yunnan Province.

Online Pharmaceutical Permit First China Pharmaceutical was certified to provide internet drug transaction services from the Yunnan Food and Drug Administration in November 2009. This is the only company that is currently authorized by the provincial government to engage in electronic commerce of pharmaceutical transactions among all levels of pharmaceutical business entities in Yunnan Province. The Company can also utilize the internet fulfillment system licensed in Yunnan Province in other provinces, thereby creating an immediate advantage over competitors throughout China. Internet transactions are subject to inspection by, and the pharmaceutical distribution company must obtain a qualification certificate from, the provincial food and drug administration. The qualification certificate is valid for five years and may be renewed by filing for an extension at least six months prior to its expiration date and undergoing a reexamination by the relevant authority. The Interim Regulations on the Examination and Approval of Providing Drug Transaction Services on the internet became effective in China on December 1, 2005 and establishes the parameters and qualifications required for providing drug transaction services on the internet, including online drug transactions between a wholesale pharmaceutical distribution company and unrelated third parties using the website of the distribution company. The qualification certificate is valid for five years and may be renewed by filing for an extension at least six months prior to its expiration date and undergoing a reexamination by the relevant authority.

Customers FCPG has over 5,000 customers, with annual sales of approximately ¥140 million. These include pharmacies (drug stores), hospitals and clinics. In urban areas, FCPG typically services customers directly, utilizing internet orders and local bonded couriers.

Approximately 1650 independents directly serviced by internet; Approximately 550 serviced by sub-distributors; and Approximately 1100 hospital, clinics and other medical institutions.

p five customers listed accounted for approximately 65% of the Company’s sales in 2009:

Chuxiong Jiayuan Medicine Co Yunnan Hongxiang Drugs Co, Ltd. Yunnan Bai Medicine Drugstore Chains Baoshan Hongyuan Medicine Company Yunnan Dragon-Horse Drugs Co, Ltd.

Competition In many of the targeted second tier and third tier cities and rural areas, competition is less intense because major drugstore chains have not entered into the market. FCPG is in a good position to establish their standing and reputation in these targeted markets. In addition, the pharmaceutical industry has entrance barriers for new entrants due to the requirements for capital, brand name and management expertise. PRC laws and regulations limit a foreign investor’s ownership in retail drugstores to the maximum of 49% if such investor holds ownership interest in more than 30 drug stores that sell a variety of branded drugs sourced from different suppliers. This limitation, together with the complexity of the Chinese market, creates a barrier for foreign retail drugstore chain operators to enter into the PRC market. Consequently, foreign owned drugstore chains competition does not exist. FCPB network covers many cities and areas, and many of drugstores are regional.

First China Pharmaceutical Group—a Healthy Growth Opportunity

Secured the only online pharmaceutical distribution license in Yunnan Province Profitable operations with significant opportunity to expand sales to existing customers and attract new customers Working to build a nationwide pharmaceutical distribution network Proprietary online ordering and fulfillment system Opportunity to expand online sales to other provinces Established sales network covering 15+ regions Existing base of 4,700 downstream customers 32,300 square feet of warehouse space Partnership with Deppon Logistics, the nation’s largest logistics company. Tremendous potential for significant return on investment

Products and Distribution As the primary supplier of 4,700 existing customers plans are in place to aggressively attract 5,000 new customers. The current 5,000 item product line of is anticipated to be expanded to 30,000 which is intended to provide the ability to supply current customers with over 80% of their pharmaceutical needs. A free personal computer will be provided to customers and so that they can place orders over the internet. To qualify for the free computer, customers will be required to guarantee that at least 60% of all orders placed will be to First China Pharmaceutical. Members will be granted special recognition and benefits, including:

More favorable payments terms Free personal computers for order placement Access to specialty drugs Discount pricing, through volume purchases

Strategic Advantage First China Pharmaceutical Group, Inc. acquired the assets of Kun Ming Xin Yuan Tang Pharmacies Co. Ltd. (XYT) of Yunnan Province (pop. 45,710,000). First China Pharmaceutical Group has a significant strategic advantage over its competitors as it has acquired the only “License of Internet Pharmacy Information Service” in Yunnan Province, enabling the organization to bypass municipal and county pharmaceutical distributors and provide products directly to its pharmacy, hospital and clinic customers. The process of reviewing applications for online drug distribution has been suspended by the Chinese government due to several cases of fraud where prescription drugs have fallen into the hands of unlicensed practitioners. First China Pharmaceutical Group will leverage its ability to fulfill orders over the internet to cut out two distribution layers and approximately 40% in total pricing markup. By bypassing city and county distributors, the Company will be able to achieve higher margins while providing pharmaceuticals to pharmacies, hospitals and clinics at costs below the current distribution model. First China Pharmaceutical’s short term objective is to broaden its product line from 5,000 products to 30,000 and include significantly more Western medicines as well as traditional Chinese drugs and herbs. By expanding its product line six-fold and offering products at a lower price than major competitors, the Company expects to be able to become its customers’ primary distributor, supplying more than 80% of the pharmaceutical products they require. In addition to selling significantly more products to its 4,700+ existing customers, the Company plans an aggressive sales and campaign to attract 5,000 new primary customers.

Advantageous Corporate Structure as a Wholly Foreign Owned Enterprise (WFOE) First China Pharmaceutical Group is a public company that owns 100% of First China Pharmaceutical Group, Limited (FCPG-HK), a Hong Kong company that in turns owns 100% of Kun Ming Xin Yuan Tang Pharmacies Co. Ltd. (XYT). This corporate structure was created to establish XYT as a Wholly Foreign Owned Enterprise (WFOE), a limited liability company operating in China and wholly owned by foreign investors. WFOE’s enjoy regulatory, revenue, currency, intellectual property protection and financial advantages over domestic joint venture partnerships in China. First China Pharmaceutical Group’s management team has a wide range of executive and operating experience. All have been involved with successful start up companies and have a thorough knowledge of the pharmaceutical industry in China. The business and operations will be conducted solely through First China Pharmaceutical Group.

Warehousing and Distribution FCPG owns a 3,000 square meter warehouse, which includes GSP certified room temperature storeroom. Deppon Logistics is the largest national logistics company in China with the ability to deliver products timely and economically. A direct sales model allows some products to be shipped from the manufacturer or national distributor to customers. Enterprise Resource Planning (“ERP”) system that is integrated with its internet ordering process enabling direct procurement of pharmaceutical products from drug manufacturers from the large national distributor, Anhui Huayuan Pharmaceutical Co.

Market Drivers

In the People’s Republic of China disposable income, standards of living, government support for healthcare, percentage of the population over sixty, and lifestyle related diseases are on the rise, creating increased health consciousness and demand for health products. With health becoming a top priority for the world’s most populous nation and second largest economy, China’s pharmaceuticals market is thriving.

The significant growth of China’s population aged 60 or above is expected to drive demand for healthcare and pharmaceutical products in China. According to the PRC National Bureau of Statistics, the proportion of the population aged 60 or above in China has increased from 11.9% in 2003, or approximately 150.0 million people, to 13.6%, or approximately 162.2 million people in 2007. Rising life expectancy is also expected to contribute to the growth of China’s aging population, both as an absolute number and as a percentage of the total population.

The aging population in China, which historically spends the most on healthcare, will drive the growth of the PRC healthcare and pharmaceutical industries. The prevalence of chronic health problems, such as arthritis, cardiovascular diseases and cancer, is expected to increase with the growth of China’s population aged 60 or above.

As living standards continue to improve and health consciousness grows in China, many lifestyle-related diseases are also increasing and becoming more widespread. For example, Business Monitor International estimates that sales of prescription cardiovascular medicines increased by 87% approximately $2.8 billion USD in 2003 to approximately $5.2 billion USD in 2007, primarily as a result of the rising prevalence of heart disease in an aging population and increasingly unhealthy lifestyles in the population at large.

According to the China Statistical Yearbook 2008 from 2003 to 2007, the average per capita annual disposable income of China’s urban residents increased from $1,250 USD $2,025 USD representing a compound annual growth rate (“CAGR”) of approximately 12.9%. China’s GDP grew at a CAGR of 16.4% from 2003 to 2007, and its per capita GDP grew from approximately $1,550 USD in 2003 to $2,780 USD in 2007, representing a CAGR of 15.8%.


According to the PRC National Bureau of Statistics, consumer expenditures on healthcare in China’s urban and rural areas increased from US$70 USD $17 USD per person in 2003, to $100 USD and $30 USD per person in 2007, respectively.

National Medical Insurance Program

The National Medical Insurance Program was introduced in 1999 and is the largest medical insurance program in China and provides guidance on which prescription and over-the-counter medicines are included in the National Program and to what extent the purchases of these medicines are reimbursable.

A small percentage of the Chinese population can afford commercial insurance plans and the National Program coverage is expected to expand in the future. According to the PRC National Bureau of Statistics, the percentage of PRC urban residents grew from approximately 37.7% of the total population to 44.9% from 2001 to 2007.

The number of people covered by the National Program increased from approximately 37.9 million in 2000 to 180.2 million in 2007, representing a CAGR of 25%. This trend is anticipated to continue as the Eleventh Five-Year Plan government development initiative projects that the PRC urban population will increase from 45% to 47% of China’s total population between 2007 to 2010.

The provincial and municipal authorities who are responsible for administering social medical insurance funds to cover reimbursements have been gradually increasing funding in recent years. According to the PRC Ministry of Labor and Social Security, total funding under the national insurance program reached $28.9 billion USD, in 2008, representing an increase of 29.2% from 2007. The availability of funding is expected to increase significantly in the near future, primarily as a result of increased financial and policy support from various levels of the PRC government.

Access to Healthcare in Rural Areas

The PRC Government has announced its goal to accelerate the reform and development of healthcare services in the PRC and focus on building a basic healthcare system that covers both rural and urban areas. The plans include providing expanded healthcare services for its rural citizens and establishing comprehensive community healthcare service centers that would provide basic medical treatment and pharmaceutical services, as well as upgrading existing class-two hospitals and state owned medical facilities.

The New Rural Cooperative Medical Insurance Scheme seeks to provide healthcare services to the vast rural areas of China. The program extends to cover approximately 2,729 counties in the PRC, which account for 95.4% of the counties in the PRC. The program also covers approximately 814 million rural residents, or approximately 91.5% of the total population engaged in the agricultural industry in China as of December 31, 2008.

It is anticipated that the New Rural Insurance Scheme will have a positive impact on the demand for pharmaceutical products in Yunnan Province, which is relatively underdeveloped with a large rural population.

PRC Healthcare Reform

Healthcare reform is anticipated to be carried out in two steps:

Step One, completed by 2011, aims to increase the accessibility while reducing the cost of healthcare. During this phase, the PRC Government will build up a network of basic healthcare facilities, expand coverage of the public medical insurance system to cover 90% or more of the population, and reform the drug supply and public hospital system.

Step Two, will take place between 2011 and 2020, and envisions the establishment of a universal healthcare system. The entire population should be covered by public medical insurance; drugs and medical services should be accessible and affordable to citizens in all public healthcare facilities.

The PRC Government has announced it will spend an $125 billion USD from 2009 to 2011 on the healthcare industry. A significant portion will be expended to establish a basic healthcare medical insurance regime, which aims to cover over 90% of the national population by 2011.

The PRC Government plans to build 29,000 rural clinics in 2009. In the next three years, the PRC government plans to build an additional 5,000 rural clinics, 2,000 county-level hospitals and 2,400 urban community clinics in under-developed areas. This substantial increase in healthcare spending is expected to expedite the growth of the healthcare industry in China.

The PRC healthcare reform plan is anticipated to benefit the pharmaceutical distribution and other business operations.

Industry Consolidation

First China Pharmaceutical plans to rapidly expand from a provincial pharmaceutical distributor in Yunnan Province to a national distributor servicing many provinces. The ordering, fulfillment and logistics network will enhance the ability to attract and acquire other provincial, county and municipal pharmaceutical distributors over the next 24 to 48 months.

The pharmaceutical distribution industry in China is currently highly fragmented. There were more than 9,000 Good Supply Practice (“GSP”) certified pharmaceutical distributors as of 2007 according to the South Medicine Economics Research Institute, an affiliate of the State Food and Drug Administration (“SFDA”). This fragmentation of the pharmaceutical industry has resulted in an inefficient supply chain for the distribution of most pharmaceutical products without the advanced logistics services featured in more developed markets.

The level of fragmentation in the pharmaceutical distribution industry, may be an indication that only large distributors with effective nationwide distribution capabilities, value-added supply chain services and large-scale operations will thrive.

First China Management First China Pharmaceutical Group’s management team has a wide range of executive and operating experience. All have been involved with successful startup companies and have a thorough knowledge of the pharmaceutical industry in China.

Mr. Zhen Jiang Wang

Chairman and Chief Executive Officer Mr. Wang founded Kun Ming Xin Yuan Tang Pharmacies Co., Ltd. (XYT) in 2002 and currently serves as General Manager. He held the position of Executive Director of Kun Ming Feng Ning Department Store from 1998 to 2001. He served as General Manager of Yun Nan Tuo Xin Equipment and Electronics Trading Co., Ltd. from 1994 to 1997. Mr. Wang graduated from He Bei Architecture Institute of P.R. China in 1994 with a degree in Architectural Engineering.

Ms. Jing Gong

President Ms. Gong founded Kun Ming Xin Yuan Tang Pharmacies Co., Ltd. (XYT) in 2002 and acted as executive director until 2009. She currently serves as General Manager. Ms. Gong served as General Manager of Kun Ming Feng Ning Department Store from 1998 to 2001. She held the position of Sales Manager of Yun Nan Tuo Xin Equipment and Electronics Trading Co., Ltd. from 1994 to 1997. Ms. Gong graduated from He Bei University of P.R. China in 1999 with a degree in Economic Management.

Mr. Yong Kang Chen

Senior Vice President, Quality Control Mr. Chen has served as Chief Supervisor of Pharmaceutical Quality of Kun Ming Xin Yuan Tang Pharmacies Co., Ltd. (XYT) since 2002. From 1997 to 2002 he held the position of Chief Supervisor for Kun Ming Municipal Pharmacies Co., Ltd. From 1990 to 1997 he served as Director of Kun Ming Pharmaceutical Inspection Department. From 1987 to 1990 Mr. Chen acted as Director of Dong Guan Science and Technology Committee. From 1983 to 1987 he was Vice Director of Dong Guan Bureau of Hygiene. From 1973 to 1983 he served as Director of Pharmaceutical Inspection of Dong Chuan City. From 1963 to 1973 Mr. Chen was Director of Pharmaceutical Section for No. 1 People’s Hospital of Dong Chuan City. Mr. Chen graduated from Nan Jing Pharmaceutical College with a Pharmacy degree in 1963.

Ms. Yi Jia Li

Chief Financial Officer Ms. Li has served as Financial Manager for Kun Ming Xin Yuan Tang Pharmacies Co., Ltd. (XYT) since 2009. From 2005 to 2009, she held the position of Financial Manager for Yun Nan Rui Ming Audio and Video Equipment Co., Ltd. From 2000 to 2005 she acted as Accounting Manager for Yun Nan Bai Feng Real Estate Co., Ltd. Ms. Li graduated from Yun Nan University in 1999 with a degree in Accounting and Audit.

Mr. Aidan Hwuang

Director Mr. Hwuang has been a partner at the Guang He Law Firm since April 2010. Previously, Mr. Hwuang served as a senior partner and the Shenzhen office manager with V&T Law Firm from August 2008 to March 2010, specializing in corporate law, acquisitions and litigation. From June 2003 to July 2008, Mr. Hwuang served as senior attorney and Shenzhen Office Manager of Lehman, Lee & Xu Law Firm. Mr. Hwuang also currently serves as the Chief Executive Officer, Chief Financial Officer, and a Director of Bakhu Holdings Corp., a publicly traded company listed on the Over-the-Counter Bulletin Board (OTCBB: BKUH). Mr. Hwuang is a member of the National Bar Association in the People’s Republic of China (“PRC”) and has over 15 years’ experience practicing law in the PRC. In addition to his Chinese law degree, Mr. Hwuang also has earned a LL.M from the University Of Aberdeen School Of Law in Scotland. Mr. Hwuang was appointed due to his over 16 years of experience practicing law in the PRC, as well as his public company leadership experience. The Company believes that Mr. Hwuang’s knowledge of the legal and business environment of the PRC will be an invaluable resource as the Company seeks to expand its business in the PRC.

Mr. Gregory D. Tse

Director Mr. Tse has over 25 years of international finance, marketing, media, PR and advertising experience with an extensive brand management track record in North America, Hong Kong and China. In China, Mr. Tse has helped many international brands to enter into the marketplace before moving on to become one of China’s first communications/media M&A specialists. Mr. Tse most recently served as Head of China Advisory for Calneva Financial Group from July 2004 to the present date, providing investment banking services for merger and acquisitions in the information technology, media, energy, infrastructure and natural resources areas. Previously, Mr. Tse’s media and marketing communications career included heading up several multinational advertising and PR agencies, including from May 1997 to June 2004, when Mr. Tse served as Managing Director at Publicis China, a communications group, were he managed the China national offices. Mr. Tse has also served as a member of the Board of Directors of i-Level Media Group Incorporated (PK: ILVL) from July 2008 to January 2009. Mr. Tse has also traveled extensively in China as the Chief Communications Officer for CORA (China’s Old Revolution Area), a NGO with a mandate to develop China’s rural areas, and started many humanitarian projects to fund education there. Mr. Tse graduated from the School of Architecture at University of Waterloo, Canada. Mr. Tse was appointed to the Company’s Board of Directors due to his over 25 years of experience, primarily in China, as well as his public company board and management experience. The Company believes that Mr. Tse’s knowledge of investment banking services and mergers and acquisitions will be an invaluable resource as the Company may seek additional capital to expand its business in the PRC in future. The Company also believes that Mr. Tse’s knowledge of brand management and marketing will aid the Company in expanding the brand awareness of its planned pharmaceutical distribution operations.

Contact Information :

First China Pharmaceutical Group, Inc.

303 Hennessey Road, Room 1301, 13th Floor Wanchai, Hong Kong, China info@firstchinapharma.com

First China Pharmaceutical Group (OTCBB: FCPG) Number 504, West Ren Min Road Yunnan Province, China Phone: 852-2138-1668

Investor Relations Evergreen Investor Relations, Inc. Phone: 1-888-518-3274 Email: info@firstchinapharma.com

About: First China Pharmaceutical Group, Inc. is a growing pharmaceutical distribution company generating significant revenue from the sale of healthcare products in China. The Company operates through newly acquired Kun Ming Xin Yuan Tang Pharmacies Co. Ltd. (XYT), a Wholly Foreign Owned Enterprise (WFOE). First China Pharmaceutical Group currently provides approximately 5,000 drugs to more than 4,700 pharmacies, hospitals and clinics in China’s Yunnan Province. First China Pharmaceutical Group is flourishing within China’s thriving market for pharmaceutical products, generating revenues of $25.3 million in 2009 and $17.2 million in 2008. Founded in 2002 and achieving profitability in 2003, the Company has grown rapidly from a small county distributor to a leading provincial pharmaceutical distributor. Securing a tremendous competitive advantage, First China is the only pharmaceutical company in the Yunnan Province licensed to fulfill pharmaceutical orders over the internet. First China Pharmaceutical Group is in position to achieve healthy near-term growth by expanding its product offerings, leveraging online ordering which will bypass several layers of middlemen including city and county distributors, increasing its customer base, and acquiring other established distributors. First China Pharmaceutical Group is the only pharmaceutical distribution company in Yunnan Province licensed by the government to fill orders over the internet. As the Provincial and National governments have placed an indefinite moratorium on granting new internet distribution licenses, First China Pharmaceutical Group possesses an extraordinary advantage over its competitors.

First China Pharmaceutical Group, Inc. (OTCBB: FCPG) StockGuru Profile – Company Website

Live Twitter Alerts All Market Day Our Twitter Feed includes all live posts from StockGuru.com.

Featured on StockGuru While we cover many companies, here are our current featured profiles on StockGuru: First China Pharmaceutical Group, Inc. (OTCBB: FCPG) GreenGold Ray Energies, Inc. (OTC: GRYE) MacroSolve, Inc. (OTCBB: MCVE) Infrax Systems, Inc. (OTCBB: IFXY) Garb Oil & Power (OTCBB: GARB)

APC Group, Inc.

(OTC: APCU) Industrial Nanotech (OTC: INTK) Medizone International (OTCBB: MZEI)  

StockGuru Spotlight Alerts Here are our latest Spotlight Alerts. Note that we typically do NOT email these to members. You must visit the site at THIS LINK to keep up to date; or you may subscribe to THIS RSS FEED .  

   

Suggest a Client: Do you know a great company that simply must be featured on StockGuru or Shareholder Vision Suggest it to us. Email: john@stockguru.com Tel: (469) 252-3031.

This entry was posted in StockGuru and tagged , , , , , , , , , , , , , , , . Bookmark the permalink.

You may also like...